Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4422661 | 1.00 | GRIN1 (0.58) | GRIN1MEN1LMNACYP1A2MAPK1 | |
| SCHEMBL499308 | 0.99 | GRIN1 (0.59) | GRIN1MEN1LMNACYP1A2MAPK1 | |
| SCHEMBL499309 | 0.99 | GRIN1 (0.59) | GRIN1MEN1LMNACYP1A2MAPK1 | |
| SCHEMBL8181067 | 0.94 | GRIN1 (0.54) | GRIN1MEN1LMNACYP1A2MAPK1 | |
| SCHEMBL8190768 | 0.93 | GRIN1 (0.55) | GRIN1MEN1LMNACYP1A2MAPK1 | |
| SCHEMBL8190756 | 0.93 | GRIN1 (0.55) | GRIN1MEN1LMNACYP1A2MAPK1 | |
| SCHEMBL8181079 | 0.92 | GRIN1 (0.54) | GRIN1MEN1LMNACYP1A2MAPK1 | |
| SCHEMBL1720270 | 0.90 | GRIN1 (0.52) | GRIN1MEN1LMNACYP1A2MAPK1 | |
| SCHEMBL30521938 | 0.90 | GRIN1 (0.52) | GRIN1MEN1LMNACYP1A2MAPK1 | |
| SCHEMBL8181069 | 0.85 | MEN1 (0.49) | GRIN1MEN1LMNACYP1A2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5962496-A | CENTRAL NERVOUS SYSTEM DISORDERS | GLAXO WELLCOME SPA (IT) | 1999-10-05 | — | — | US | claimed |
| US-5760059-A | ANTAGONISTS OF EXCITATORY AMINO ACIDS, TREATMENT OF NEURODEGENERATIVE DISEASES | GLAXO WELLCOME SPA (IT) | 1998-06-02 | — | — | US | claimed |
| US-20240156853-A1 | IN VITRO AND IN VIVO INTRACELLULAR DELIVERY OF SIRNA VIA SELF-ASSEMBLED NANOPIECES | RHODE ISLAND HOSPITAL | 2024-05-16 | — | — | US | disclosed |
| US-11701379-B2 | In vitro and in vivo intracellular delivery of siRNA via self-assembled nanopieces | RHODE ISLAND HOSPITAL (US) | 2023-07-18 | — | — | US | disclosed |
| US-11147799-B2 | Topical pharmaceutical composition containing phenytoin and a (co-) analgesic for the treatment of chronic pain | Keppel Hesselink, Jan Marius (NL) | 2021-10-19 | — | — | US | disclosed |
| CN-106793970-B | Nanoparring agents for diagnosis and therapy and processing thereof | 罗得岛医院 | 2021-07-30 | — | — | CN | disclosed |
| US-20210023117-A1 | IN VITRO AND IN VIVO INTRACELLULAR DELIVERY OF SIRNA VIA SELF-ASSEMBLED NANOPIECES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-01-28 | — | — | US | disclosed |
| US-20200375991-A1 | NANOCARRIERS AND THEIR PROCESSING FOR DIAGNOSTICS AND THERAPEUTICS | RHODE ISLAND HOSPITAL | 2020-12-03 | — | — | US | disclosed |
| US-20200069649-A1 | TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHENYTOIN AND A (CO -) ANALGESIC FOR THE TREATMENT OF CHRONIC PAIN | TOPICAL INNOVATIONS B.V. (NL) | 2020-03-05 | — | — | US | disclosed |
| US-10555948-B2 | Nanocarriers and their processing for diagnostics and therapeutics | RHODE ISLAND HOSPITAL (US) | 2020-02-11 | — | — | US | disclosed |
| EP-3551182-A1 | TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHENYTOIN AND A (CO -)AN ALGESIC FOR THE TREATMENT OF CHRONIC PAIN | TOPICAL INNOVATIONS B.V. (NL) | 2019-10-16 | — | — | EP | disclosed |
| WO-2006079055-A2 | APPARATUS AND METHOD FOR DELIVERING THERAPEUTIC AND/OR OTHER AGENTS TO THE INNER EAR AND TO OTHER TISSUES | NEUROSYSTEC CORPORATION (US) | 2006-07-27 | — | — | WO | disclosed |
| US-6239287-B1 | REACTING THE CORRESPONDING BROMO COMPOUND WITH A PHOSPHINE | GLAXO WELLCOME SPA (IT) | 2001-05-29 | — | — | US | disclosed |
| US-6100289-A | ADMINISTERING AN ANALGESIC AMOUNT OF EXCITATORY AMINO ACID ANTAGONIST TO MAMMAL | GLAXO WELLCOME SPA (IT) | 2000-08-08 | — | — | US | disclosed |
| EP-0966463-A1 | CRYSTALLINE HYDRATED SODIUM SALT OF (E)-4,6-DICHLORO-3-(2-OXO-1-PHENYLPYRROLIDIN-3-YLIDENE METHYL)-1H-INDOLE-2-CARBOXYLIC ACID | GLAXO WELLCOME S.p.A. (IT) | 1999-12-29 | — | — | EP | disclosed |
| EP-0966475-A1 | PREPARATION OF PHOSPHONIUM COMPOUNDS AS INTERMEDIATES FOR GLYCINE ANTAGONISTS | GLAXO WELLCOME S.p.A. (IT) | 1999-12-29 | — | — | EP | disclosed |
| US-5962496-A | CENTRAL NERVOUS SYSTEM DISORDERS | GLAXO WELLCOME SPA (IT) | 1999-10-05 | — | — | US | disclosed |
| WO-1998039327-A1 | CRYSTALLINE HYDRATED SODIUM SALT OF (E)-4,6-DICHLORO-3-(2-OXO-1-PHENYLPYRROLIDIN-3-YLIDENE METHYL)-1H-INDOLE-2-CARBOXYLIC ACID | GLAXO WELLCOME S.P.A. (IT) | 1998-09-11 | — | — | WO | disclosed |
| WO-1998039341-A1 | PREPARATION OF PHOSPHONIUM COMPOUNDS AS INTERMEDIATES FOR GLYCINE ANTAGONISTS | GLAXO WELLCOME S.P.A. (IT) | 1998-09-11 | — | — | WO | disclosed |
| US-5760059-A | ANTAGONISTS OF EXCITATORY AMINO ACIDS, TREATMENT OF NEURODEGENERATIVE DISEASES | GLAXO WELLCOME SPA (IT) | 1998-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701379-B2 | In vitro and in vivo intracellular delivery of siRNA via self-assembled nanopieces | NFATC1, TRAF6, UACA | GRIN1 2951/4885MEN1 3021/4885LMNA 415/4885 |
| US-20210023117-A1 | IN VITRO AND IN VIVO INTRACELLULAR DELIVERY OF SIRNA VIA SELF-ASSEMBLED NANOPIECES | NFATC1, TRAF6, UACA | GRIN1 2951/4885MEN1 3021/4885LMNA 415/4885 |
| US-10555948-B2 | Nanocarriers and their processing for diagnostics and therapeutics | SYVN1, SSB, TNF | GRIN1 4102/4885MEN1 3527/4885LMNA 379/4885 |
| US-20200375991-A1 | NANOCARRIERS AND THEIR PROCESSING FOR DIAGNOSTICS AND THERAPEUTICS | SYVN1, SSB, TNF | GRIN1 4102/4885MEN1 3527/4885LMNA 379/4885 |
| US-20240156853-A1 | IN VITRO AND IN VIVO INTRACELLULAR DELIVERY OF SIRNA VIA SELF-ASSEMBLED NANOPIECES | NFATC1, TRAF6, UACA | GRIN1 2951/4885MEN1 3021/4885LMNA 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.